Mucinous carcinoma of the breast is genomically distinct from invasive ductal carcinomas of no special type

Journal of Pathology

Volumn 222, Issue 3, 2010, Pages 282-298

  Lacroix Triki, Magali ^a,b   Suarez, Paula H ^a   Mackay, Alan ^a   Lambros, Maryou B ^a   Natrajan, Rachael ^a   Savage, Kay ^a   Geyer, Felipe C ^a   Weigelt, Britta ^c   Ashworth, Alan ^a   Reis Filho, Jorge S ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUT CLAUDIUS REGAUD   (France)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

Colloid carcinoma; Comparative genomic hybridization; Genetics; Immunohistochemistry; In situ hybridization; Microarrays

Indexed keywords

CORTACTIN; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53; UVOMORULIN; WT1 PROTEIN; TUMOR PROTEIN;

ARTICLE; BREAST CARCINOMA; COMPARATIVE GENOMIC HYBRIDIZATION; GENE AMPLIFICATION; GENOMICS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INTRADUCTAL CARCINOMA; MICROARRAY ANALYSIS; MUCINOUS CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; BREAST TUMOR; CHROMOSOME ABERRATION; CLUSTER ANALYSIS; COLLOID CARCINOMA; FEMALE; GENE EXPRESSION PROFILING; GENETICS; LYMPH NODE METASTASIS; METABOLISM; ONCOGENE; PAGET NIPPLE DISEASE; PATHOLOGY; PROCEDURES; TUMOR INVASION;

ADENOCARCINOMA, MUCINOUS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CHROMOSOME ABERRATIONS; CLUSTER ANALYSIS; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; HUMANS; LYMPHATIC METASTASIS; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; ONCOGENES;

EID: 77958022477     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2763     Document Type: Article

References (59)

1. Tavassoli FA, Devilee P (eds). Tumours of the Breast. International Agency for Research of Cancer (IARC): Lyon, 2003.
2. Weigelt B, Reis-Filho JS. Histological and molecular types of breast cancer: is there a unifying taxonomy? Nature Rev Clin Oncol 2009;6:718-730.
3. Weigelt B, Geyer FC, Reis-Filho JS. Histological types of breast cancer: how special are they? Mol Oncol 2010;4:192-208.
4. Weigelt B, Horlings HM, Kreike B, et al. Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol 2008;216:141-150.
5. Reis-Filho JS, Lakhani SR. Breast cancer special types: why bother? J Pathol 2008;216:394-398.
6. Weigelt B, Baehner FL, Reis-Filho JS. The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J Pathol 2010;220:263-280.
7. Vo T, Xing Y, Meric-Bernstam F, et al. Long-term outcomes in patients with mucinous, medullary, tubular, and invasive ductal carcinomas after lumpectomy. Am J Surg 2007;194:527-531.
8. Li CI, Uribe DJ, Daling JR. Clinical characteristics of different histologic types of breast cancer. Br J Cancer 2005;93:1046-1052.
9. Barkley CR, Ligibel JA, Wong JS, et al. Mucinous breast carcinoma: a large contemporary series. Am J Surg 2008;196:549-551.
10. Capella C, Eusebi V, Mann B, et al. Endocrine differentiation in mucoid carcinoma of the breast. Histopathology 1980;4:613-630.
11. Weigelt B, Geyer FC, Horlings HM, et al. Mucinous and neuroendocrine breast carcinomas are transcriptionally distinct from invasive ductal carcinomas of no special type. Mod Pathol 2009;22:1401-1414.
12. Komaki K, Sakamoto G, Sugano H, et al. Mucinous carcinoma of the breast in Japan. A prognostic analysis based on morphologic features. Cancer 1988;61:989-996.
13. Toikkanen S, Kujari H. Pure and mixed mucinous carcinomas of the breast: a clinicopathologic analysis of 61 cases with long-term follow-up. Hum Pathol 1989;20:758-764.
14. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19:403-410.
15. Natrajan R, Lambros MB, Geyer FC, et al. Loss of 16q in high grade breast cancer is associated with estrogen receptor status: evidence for progression in tumors with a luminal phenotype? Genes Chromosomes Cancer 2009;48:351-365.
16. Natrajan R, Lambros MB, Rodriguez-Pinilla SM, et al. Tiling path genomic profiling of grade 3 invasive ductal breast cancers. Clin Cancer Res 2009;15:2711-2722.
17. Loo LW, Grove DI, Williams EM, et al. Array comparative genomic hybridization analysis of genomic alterations in breast cancer subtypes. Cancer Res 2004;64:8541-8549.
18. Melchor L, Honrado E, Huang J, et al. Estrogen receptor status could modulate the genomic pattern in familial and sporadic breast cancer. Clin Cancer Res 2007;13:7305-7313.
19. Marchio C, Iravani M, Natrajan R, et al. Genomic and immunophenotypical characterization of pure micropapillary carcinomas of the breast. J Pathol 2008;215:398-410.
20. Marchio C, Iravani M, Natrajan R, et al. Mixed micropapillary-ductal carcinomas of the breast: a genomic and immunohistochemical analysis of morphologically distinct components. J Pathol 2009;218:301-315.
21. Marchio C, Lambros MB, Gugliotta P, et al. Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis. J Pathol 2009;219:16-24.
22. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004;10:5367-5374.
23. Lambros MB, Simpson PT, Jones C, et al. Unlocking pathology archives for molecular genetic studies: a reliable method to generate probes for chromogenic and fluorescent in situ hybridization. Lab Invest 2006;86:398-408.
24. Marchio C, Natrajan R, Shiu KK, et al. The genomic profile of HER2-amplified breast cancers: the influence of ER status. J Pathol 2008;216:399-407.
25. Coe BP, Ylstra B, Carvalho B, et al. Resolving the resolution of array CGH. Genomics 2007;89:647-653.
26. Gunnarsson R, Staaf J, Jansson M, et al. Screening for copynumber alterations and loss of heterozygosity in chronic lymphocytic leukemia-a comparative study of four differently designed, high resolution microarray platforms. Genes Chromosomes Cancer 2008;47:697-711.
27. Tan DS, Lambros MB, Natrajan R, et al. Getting it right: designing microarray (and not 'microawry') comparative genomic hybridization studies for cancer research. Lab Invest 2007;87:737-754.
28. Mackay A, Tamber N, Fenwick K, et al. A high-resolution integrated analysis of genetic and expression profiles of breast cancer cell lines. Breast Cancer Res Treat 2009;118:481-498.
29. Natrajan R, Weigelt B, Mackay A, et al. An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers. Breast Cancer Res Treat 2010;121:575-589.
30. Reis-Filho JS, Drury S, Lambros MB, et al. ESR1 gene amplification in breast cancer: a common phenomenon? Nature Genet 2008;40:809-810; author reply 810-802.
31. Turner N, Lambros MB, Horlings HM, et al. Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene 2010;29:2013-2023.
32. Clark ES, Brown B, Whigham AS, et al. Aggressiveness of HNSCC tumors depends on expression levels of cortactin, a gene in the 11q13 amplicon. Oncogene 2009;28:431-444.
33. Quinlan KG, Verger A, Yaswen P, et al. Amplification of zinc finger gene 217 (ZNF217) and cancer: when good fingers go bad. Biochim Biophys Acta 2007;1775:333-340.
34. Ormandy CJ, Musgrove EA, Hui R, et al. Cyclin D1, EMS1 and 11q13 amplification in breast cancer. Breast Cancer Res Treat 2003;78:323-335.
35. Reis-Filho JS, Savage K, Lambros MB, et al. Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis. Mod Pathol 2006;19:999-1009.
36. Elsheikh S, Green AR, Aleskandarany MA, et al. CCND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome. Breast Cancer Res Treat 2008;109:325-335.
37. Dedes KJ, Lopez-Garcia MA, Geyer FC, et al. Cortactin gene amplification and expression in breast cancer: a chromogenic in situ hybridisation and immunohistochemical study. Breast Cancer Res Treat 2010; DOI: 10.1007/s10549-10010-10816-10540.
38. Lambros MB, Natrajan R, Geyer FC, et al. PPM1D gene amplification and overexpression in breast cancer: a qRT-PCR and chromogenic in situ hybridization study. Mod Pathol 2010; DOI: 10.1038/modpathol.2010.1121.
39. Domfeh AB, Carley AL, Striebel JM, et al. WT1 immunoreactivity in breast carcinoma: selective expression in pure and mixed mucinous subtypes. Mod Pathol 2008;21:1217-1223.
40. Hicks J, Krasnitz A, Lakshmi B, et al. Novel patterns of genome rearrangement and their association with survival in breast cancer. Genome Res 2006;16:1465-1479.
41. Fujii H, Anbazhagan R, Bornman DM, et al. Mucinous cancers have fewer genomic alterations than more common classes of breast cancer. Breast Cancer Res Treat 2002;76:255-260.
42. Simpson PT, Reis-Filho JS, Gale T, et al. Molecular evolution of breast cancer. J Pathol 2005;205:248-254.
43. Abdel-Fatah TM, Powe DG, Hodi Z, et al. High frequency of coexistence of columnar cell lesions, lobular neoplasia, and low grade ductal carcinoma in situ with invasive tubular carcinoma and invasive lobular carcinoma. Am J Surg Pathol 2007;31:417-426.
44. Reis-Filho JS, Simpson PT, Turner NC, et al. FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. Clin Cancer Res 2006;12:6652-6662.
45. Bertucci F, Orsetti B, Negre V, et al. Lobular and ductal carcinomas of the breast have distinct genomic and expression profiles. Oncogene 2008;27:5359-5372.
46. Abdel-Fatah TM, Powe DG, Hodi Z, et al. Morphologic and molecular evolutionary pathways of low nuclear grade invasive breast cancers and their putative precursor lesions: further evidence to support the concept of low nuclear grade breast neoplasia family. Am J Surg Pathol 2008;32:513-523.
47. Aparicio SA, Huntsman DG. Does massively parallel DNA resequencing signify the end of histopathology as we know it? J Pathol 2010;220:307-315.
48. Reis-Filho JS. Next-generation sequencing. Breast Cancer Res 2009;11(Suppl 3): S12.
49. Wong KK, deLeeuw RJ, Dosanjh NS, et al. A comprehensive analysis of common copy-number variations in the human genome. Am J Hum Genet 2007;80:91-104.
50. Iafrate AJ, Feuk L, Rivera MN, et al. Detection of large-scale variation in the human genome. Nat Genet 2004;36:949-951.
51. Harvey JM, Clark GM, Osborne CK, et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999;17:1474-1481.
52. Reis-Filho JS, Pinheiro C, Lambros MB, et al. EGFR amplification and lack of activating mutations in metaplastic breast carcinomas. J Pathol 2006;209:445-453.
53. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-145.
54. Callagy GM, Pharoah PD, Pinder SE, et al. Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index. Clin Cancer Res 2006;12:2468-2475.
55. Tan DS, Marchio C, Jones RL, et al. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat 2008;111:27-44.
56. Mahler-Araujo B, Savage K, Parry S, et al. Reduction of E-cadherin expression is associated with non-lobular breast carcinomas of basal-like and triple negative phenotype. J Clin Pathol 2008;61:615-620.
57. Savage K, Lambros MB, Robertson D, et al. Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clin Cancer Res 2007;13:90-101.
58. Savage K, Leung S, Todd SK, et al. Distribution and significance of caveolin 2 expression in normal breast and invasive breast cancer: an immunofluorescence and immunohistochemical analysis. Breast Cancer Res Treat 2008;110:245-256.
59. Parry S, Savage K, Marchio C, et al. Nestin is expressed in basallike and triple negative breast cancers. J Clin Pathol 2008;61:1045-1050.